

Esophageal Oncology group : Treatment map Jan.2024.

UICC 8th	Standard treatment in Japan		Trials ongoing or follow up	
Stage I (N0)	Endoscopic resection (ESD/EMR) + CRT		JCOG2013 (±NeoCF ² /DCF ³) Esophagectomy: Upper and Middle thoracic Esophageal Squamous Cell Cancer SCLN ⁸ Dissection vs Preservation 2022/8~ Ongoing	JCOG1904 CRT: IFI ⁵ vs. ENI ⁶ 2020/03~ Ongoing
	Esophagectomy (Thoracoscopic or open esophagectomy) ¹	Concurrent CRT (CF-RT ⁴)		
Stage I (N1)	Neoadjuvant chemotherapy (Neo DCF ³) + Esophagectomy (Thoracoscopic or open esophagectomy) ¹	Adjuvant Nivolumab (Neo CRT + Esophagectomy)	Concurrent CRT (CF-RT ⁴) (+Salvage esophagectomy or endoscopic resection)	JCOG1804E Neo CF ² /DCF ³ /FLOT ⁷ +Nivolumab +Esophagectomy 2019/3~ Follow up period
Stage II				
Stage III				JCOG2206 NeoCF ² /DCF ³ +Esophagectomy: Surgery alone vs Nivolumab vs S-1 2023/7~ Ongoing
T4a/M1LYM Resectable	Neoadjuvant chemotherapy + Esophagectomy ¹	Concurrent CRT		
T4b/M1LYM Unresectable	Concurrent CRT		JCOG1510 Concurrent CRT vs. Induction DCF ³ + Concurrent CRT or Esophagectomy 2018/2~2023.4→2026.4 Follow up period	
Stage IVB	1 st line chemotherapy: CF ² + Pembrolizumab CF ² +Nivolumab Nivolumab + Ipilimumab	2 nd line chemotherapy: Paclitaxel Docetaxel If no previous ICIs ¹² : Nivolumab Pembrolizumab (CPS ≥10)		
Recurrent				

1) 2-3 field lymph node dissection 2) CF, CDDP + 5-FU 3) DCF, DOC + CDDP + 5-FU 4) CF-RT, CDDP + 5-FU + radiation therapy
5) IFI, Involved field irradiation 6) ENI, Elective lymph node irradiation 7) FLOT, 5-FU + LV + L-OHP + DOC 8) SCLN, Supraclavicular lymph node
9) EGJ, Esophagogastric junction 10) DOS, DOC + L-OHP + S-1 11) ICI, Immune checkpoint inhibitor